Publikationen von Tjalf Ziemssen

Kawakami, N.; Odoardi, F.; Ziemssen, T.; Bradl, M.; Ritter, T.; Neuhaus, O.; Lassmann, H.; Wekerle, H.; Flügel, A.: Autoimmune CD4(+) T cell memory: Lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. Journal of Immunology 175 (1), S. 69 - 81 (2005)

Ziemssen, T.; Kümpfel, T.; Schneider, H.; Klinkert, W. E. F.; Neuhaus, O.; Hohlfeld, R.: Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. Journal of the Neurological Sciences 233 (1-2), S. 109 - 112 (2005)

Kawakami, N.; Lassmann, S.; Li, Z. X.; Odoardi, F.; Ritter, T.; Ziemssen, T.; Klinkert, W. E. F.; Ellwart, J. W.; Bradl, M.; Krivacic, K. et al.; Lassmann, H.; Ransohoff, R. M.; Volk, H. D.; Wekerle, H.; Linington, C.; Flügel, A.: The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. Journal of Experimental Medicine 199 (2), S. 185 - 197 (2004)

Ziemssen, T.; Kümpfel, T.; Klinkert, W. E. F.; Neuhaus, O.; Hohlfeld, R.: Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy. Brain 125, S. 2381 - 2391 (2002)

Ziemssen, T.; Neuhaus, O.; Farina, C.; Hartung, H. P.; Hohlfeld, R.: Treatment of multiple sclerosis with glatiramer acetate - new information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies. Nervenarzt 73 (4), S. 321 - 331 (2002)

Ziemssen, T.; Neuhaus, O.; Hohlfeld, R.: Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety 24 (13), S. 979 - 990 (2002)

Ziemssen, T.: Neuroprotection and glatiramer acetate: The possible role in the treatment of Multiple Sclerosis. In: FRONTIERS IN CLINICAL NEUROSCIENCE: NEURODEGENERATION AND NEUROPROTECTION, S. 111 - 134 (Hg. Vecsei, L.). KLUWER ACADEMIC/PLENUM PUBL, NEW YORK (2004)